Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Dividend history for Theseus Pharmaceuticals, Inc. (THRX)
Theseus Pharmaceuticals, Inc. made a total of 5 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $1.25
Dividend payments for Theseus Pharmaceuticals, Inc. (THRX) from 2014 to 2015
Annual dividend payments
| Date | Dividend | Adj Dividend |
|---|---|---|
| September 08, 15 | $0.25 | $0.25 |
| June 10, 15 | $0.25 | $0.25 |
| March 10, 15 | $0.25 | $0.25 |
| November 21, 14 | $0.25 | $0.25 |
| August 26, 14 | $0.25 | $0.25 |